Our characterization of INK128 in combination with trametinib or cobimetinib in multiple cell line models of MPNST suggests a clinical trial that specifically aims to investigate this agent in patients with NF1-associated tumors may prove a promising avenue for investigation. The gene discussed is NF1; the disease is malignant peripheral nerve sheath tumor.